A Pilot Study to Assess the DynaSense System

August 10, 2014 updated by: Leaf Healthcare, Inc.

The study is designed to test the DynaSense system, which is a patient movement and orientation monitoring system. The study is intended to determine that:

  • the DynaSense system identifies patients that are not turning adequately on their own and therefore require caregiver-assisted turns.
  • the DynaSense system identifies patients that are turning adequately on their own and therefore do not require a caregiver-assisted turn.
  • the DynaSense system helps ensure compliance with an institution's established patient turning protocol.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Mountain View, California, United States, 94040
        • El Camino Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult male or female 18 to 110 years of age;
  • Inpatient currently on the unit and expected to remain for at least 12 hours;
  • Able and willing to comply with the study procedures;
  • Subject (or his/her agent) is able to read, understand, and provide Informed Consent in the English language.

Exclusion Criteria:

  • Subject is a female subject under the age of 60 who is pregnant, planning on becoming pregnant, or is currently breastfeeding.

    1. Any woman under the age of 60, must have a negative urine pregnancy test prior to being enrolled in the study; OR
    2. Be postmenopausal for at least 2 years, OR
    3. have had a bilateral tubal ligations, OR
    4. have had a bilateral oophorectomy, OR
    5. have had a hysterectomy.
  • Subjects with a known tape allergy or sensitivity to EKG leads or similar types of adhesives used in common medical products.
  • Subjects who cannot have the patient sensor applied on the surface of the patient's anterior torso.
  • Subjects who have a pacemaker or implantable cardiovascular-defibrillator (ICD).
  • Subjects with dementia, Alzheimer's disease or other mental disabilities and incapacitation that would prevent the subject from providing written informed consent. If the subject is unable to provide informed consent due to mental incapacity, then the subject's Durable Power of Attorney may provide informed consent and sign the informed consent on behalf of the subject.
  • Subjects who refuse to have an area of hair on their chest be clipped or shaved, if needed for patient sensor adhesion.
  • Subjects, who in the opinion of the Principal Investigator, are at increased risk by participating in the clinical study.
  • Subjects who have participated in another clinical study within the past 30 days or are currently participating in another clinical study at the time of screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: DynaSense sensor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety Primary Endpoint
Time Frame: Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.
The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.
Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.
Turn Protocol Compliance
Time Frame: Subjects will be followed for the length of hospital stay which is expected to average 5 days.
The primary clinical efficacy endpoint is to assess the change in turning protocol compliance after implementation of the DynaSense system.
Subjects will be followed for the length of hospital stay which is expected to average 5 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Michelle Pezzani, MD, El Camino Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2013

Primary Completion (ACTUAL)

February 1, 2014

Study Completion (ACTUAL)

February 1, 2014

Study Registration Dates

First Submitted

November 27, 2013

First Submitted That Met QC Criteria

December 4, 2013

First Posted (ESTIMATE)

December 9, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

August 13, 2014

Last Update Submitted That Met QC Criteria

August 10, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CM-002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pressure Ulcers

Clinical Trials on DynaSense sensor

3
Subscribe